EUVIMEDEUVIMED entdecken
Crossref

Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways

Tian Fang, Shiheng Hu, Xinhao Song, Junqi Wang, Runan Zuo, Shifeng Yun, Shanxiang Jiang, Dawei Guo

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07374-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Tian Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 We…. Hauptthemen laut MEDLINE: Erlotinib Hydrochloride, Triple Negative Breast Neoplasms, Neoplastic Stem Cells, ErbB Receptors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cancer stem cells (CSCs) in triple-negative breast cancer (TNBC) are recognized as a highly challenging subset of cells, renowned for their heightened propensity for relapse and unfavorable prognosis. Monensin, an ionophoric antibiotic, has been reported to exhibit significant therapeutic efficacy against various cancers, especially CSCs. Erlotinib is classified as one of the EGFR-TKIs and has been previously identified as a promising therapeutic target for TNBC. Our research aims to assess the effectiveness of combination of monensin and erlotinib as a potential treatment strategy for TNBC. METHODS: The combination of monensin and erlotinib was assessed for its potential anticancer activity through various in vitro assays, including cytotoxicity assay, colony formation assay, wound healing assay, transwell assay, mammosphere formation assay, and proportion of CSCs assay. Additionally, an in vivo study using tumor-bearing nude mice was conducted to evaluate the inhibitory effect of the monensin and erlotinib combination on tumor growth. RESULTS: The results indicated that combination of monensin with erlotinib synergistically inhibited cell proliferation, the migration rate, the invasion ability and decreased the CSCs proportion, and CSC markers SOX2 and CD133 in vivo and in vitro. Furthermore, the primary proteins involved in the signaling pathways of the EGFR/ERK and PI3K/AKT are simultaneously inhibited by the combination treatment of monensin and erlotinib in vivo and in vitro. CONCLUSIONS: The simultaneous inhibition of the EGFR/ERK and PI3K/AKT/mTOR signaling pathways by the combination of monensin and erlotinib exhibited a synergistic effect on suppressing tumor proliferation and cancer cell stemness in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erlotinib HydrochlorideTriple Negative Breast NeoplasmsNeoplastic Stem CellsErbB ReceptorsSignal TransductionMonensinCell ProliferationXenograft Model Antitumor AssaysDrug SynergismHumansAnimalsFemaleMiceCell Line, TumorPhosphatidylinositol 3-KinasesCell MovementAntineoplastic Combined Chemotherapy ProtocolsMice, Nude

Stichwörter der Autor:innen

Cancer stem cellsEGFR/PI3KErlotinibMonensinTriple-negative breast cancer

Substanzen

Erlotinib HydrochlorideErbB ReceptorsMonensinEGFR protein, humanPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.
  • MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China.
  • Department of Comparative Medicine, Affiliated Hospital of Medicine School, Nanjing Jinling Hospital, Nanjing University, Nanjing, 210002, China.
  • Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. jiangshanxiang@163.com.
  • MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. jiangshanxiang@163.com.
  • Engineering Center of Innovativennovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, 1 Weigang, Nanjing, 210095, China. gdawei0123@njau.edu.cn.

Förderung

  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions

Zitieren

APA

Fang, T., Hu, S., Song, X., Wang, J., Zuo, R., Yun, S., Jiang, S., & Guo, D. (2024). Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07374-y

Vancouver

Fang T, Hu S, Song X, Wang J, Zuo R, Yun S, et al. Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07374-y

BibTeX
@article{Fang2024,
  author = {Fang, Tian and Hu, Shiheng and Song, Xinhao and Wang, Junqi and Zuo, Runan and Yun, Shifeng and Jiang, Shanxiang and Guo, Dawei},
  title = {Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07374-y}
}
Kostenlos starten →